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INTRODUCTION 
The twentieth century saw unparalleled increase in life 
expectancy and a major shift in the cause of illness and death throughout 
the world. During this transition cardiovascular disease became the most 
common cause of death worldwide. A century ago CVD accounted for 
less than 10% of all deaths. Today it accounts for approximately 30% of 
deaths worldwide including nearly 40% in high-income countries and 
28% in low and middle-income countries. Driven by industrialization and 
associated lifestyle changes, this ongoing transition is occurring around 
the world among all races, ethnic groups and cultures at an even faster 
rate than last century1. 
Based on data from Framingham heart study, the lifetime risk of 
developing symptomatic CAD after age forty is 49% for men and 32% 
for women. The World Health Organization has estimated that by 2020, 
the global number of deaths from CAD will have risen from 7.2 million 
in 2002 to 11.1 million2. The evaluation of IHD in women presents a 
unique and sometimes difficult challenge for clinicians, owing to the 
difference in symptoms, clinical features and mortality as compared to 
men. The diagnosis and treatment of CHD have been primarily based on 
research conducted in men, either excluding women entirely or including 
limited number of women. The use of traditional risk factors assessment 
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was limited in prediction of CAD in women3. The compendium of 
coronary heart disease data indicate that current research and strategy 
development must focus on gender-specific issues in order to address the 
societal burden and costs related to these demographic shifts in IHD that 
place women in the majority of those impacted. This significant burden of 
the disease in women places unique diagnostic, treatment, and financial 
encumbrances on our society that are only further intensified by a lack of 
public awareness about the disease on the part of patients and clinicians 
alike. This societal burden of the disease is, in part, related to our poor 
understanding of gender-specific pathophysiologic differences in the 
presentation and prognosis of IHD and the paucity of diagnostic and 
treatment guidelines tailored to phenotypic differences in women4. 
This study is to analyse the clinical presentation, complications 
and outcome in those women who presented with myocardial infarction. 
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AIM OF THE STUDY 
1. To analyse the various risk factors in women with acute myocardial 
infarction. 
2. To study the presenting features, site of infarction and 
complications of acute myocardial infarction in women. 
3. To study the outcome in women with acute myocardial infarction 
admitted to coronary care unit. 
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REVIEW OF LITERATURE 
The clinical presentations of CAD are highly variable. Chest 
discomfort is usually the predominant symptom in chronic stable angina, 
unstable angina, micro vascular angina and acute myocardial infarction. 
However syndromes of CAD also occur in which ischemic chest comfort 
is absent or not prominent such as asymptomatic myocardial ischemia, 
congestive heart failure, cardiac arrhythmias and sudden death. 
The contemporary approach to patients presenting with ischemic 
discomfort is to consider that they are experiencing an acute coronary 
syndrome. The twelve lead ECG is pivotal for segregating patients into 
those presenting with ST segment elevation and those presenting without 
ST segment elevation. 
Despite the gratifying success of medical therapy for STEMI, 
several observations indicate considerable room for improvement. 
Advanced age consistently emerge as one of the principal determinants of 
mortality in patients with STEMI. Variations have also been observed in 
the treatment patterns of certain population subgroups with STEMI, 
notably women2. Nevertheless, evidence suggests that the greatest 
reductions in mortality for elderly patients derive from those strategies 
employed during the first 24 hours, a time frame in which prompt and 
appropriate use of life-saving reperfusion therapy has paramount 
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importance, emphasizing the need to extend advances in drug therapy for 
STEMI to the elderly. 
Revised definition of Myocardial Infarction Criteria for Acute, 
Evolving or Recent MI2 
Either of the following criteria satisfies the diagnosis for acute, 
evolving or recent MI: 
1. Typical rise and/ or fall of biochemical markers of myocardial 
necrosis with atleast one of the following: 
a) Ischemic symptoms 
b) Development of pathological Q waves in ECG 
c) ECG changes indicative of ischemia (ST segment 
elevation or depression) 
d) Imaging evidence of new loss of viable myocardium or 
new regional wall motion abnormality. 
2. Pathological findings of an acute myocardial infarction. 
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Pathology 
Almost all MI’s result from coronary atherosclerosis, generally 
with superimposed coronary thrombosis. Non atherogenic forms of 
coronary artery disease are uncommon. 
Causes of myocardial infarction without coronary atherosclerosis: 
1. Arteritis 
2. Trauma to coronary arteries 
3. Coronary mural thickening with metabolic disease or intimal 
proliferative disease 
4. Spasm of coronary arteries 
5. Emboli 
6. Congenital coronary artery anomalies 
7. Myocardial oxygen demand – supply disproportion 
8. Hematological (in situ thrombosis) 
9. Miscellaneous: cocaine abuse, myocardial contusion 
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Atherothrombosis: 
Atherothrombosis can no longer be considered a disease of the 
developed world because of myocardial infarction and stroke is 
increasingly prevalent worldwide across all socioeconomic strata. 
Conventional risk factors: 
1. Smoking: 
 Other than advanced age, smoking is the single most important risk 
factor for coronary artery disease. Ischemic heart disease causes 35 to 40 
percent of all smoking related deaths, with an additional 8 percent 
attributable to second hand smoke exposure. An exceptionally consistent 
series of studies suggest that, compared with nonsmokers, persons who 
consume 20 or more cigarettes daily have a two to three fold increase in 
fatal coronary artery disease. Historically, cigarette consumption was 
prevalent in men, however this gender gap has markedly narrowed, with 
overall consumption rates in women is excess of 20 percent. 
2. Hypertension: 
 High blood pressure often confers silent cardiovascular risk and its 
prevalence is steadily increasing. Of the estimated 50 million people with 
high blood pressure, almost one third evade diagnosis and only one fourth 
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receive effective treatment. Hypertension prevalence increased with age 
(reaching more than 65 percent after the age of 60 years) and tended to be 
more prevalent in women than men. In the Framingham heart study, even 
high normal blood pressure (systolic blood pressure 130 to 139 mm Hg, 
diastolic blood pressure 85 to 89 mm Hg or both) augments risk of 
cardiovascular disease two fold compared with lower levels. 
 The most recent report from the Joint National Committee on 
prevention, detection, evaluation and treatment of high blood pressure   
(JNC VII) has continued appropriately to stress weight control, adoption 
of the DASH diet with sodium restriction, increased intake of potassium 
and calcium rich foods, moderate alcohol consumption to fewer than two 
drinks daily and increased physical activity. 
Staging of office blood pressure: 
Blood pressure stage Systolic BP  Diastolic BP  
Normal <120 mm Hg <80 mm Hg 
Prehypertension 120 – 139 mm Hg 80 – 89 mm Hg 
Stage 1 hypertension 140 – 159 mm Hg 90 – 99 mm Hg 
Stage 2 hypertension ≥160 mm Hg ≥100 mm Hg 
Isolated systolic hypertension >140 mm Hg <90 mm Hg 
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3. Hyperlipidemia and elevated low density lipoprotein 
 cholesterol: 
The emergence of data from prospective cohort studies such as 
Framingham heart study, The multiple risk factor intervention trial 
(MRFIT), Atherosclerosis risk in communities (ARIC) study established 
the concept of cholesterol as a culprit in coronary heart disease. 
4. High density lipoprotein cholesterol, apolipoproteins and other 
lipid subclasses: 
Abundant prospective cohort studies have demonstrated a strong 
inverse relationship between HDL cholesterol and vascular risk. Despite 
evidence favouring apolipoprotein AΙ and B 100 as replacements for 
HDL and LDL cholesterol, there remains little clinical data that use of 
these measures improve overall risk prediction. 
5. Triglyceride rich lipoprotein: 
The role of triglyceride in atherogenesis remains controversial. A 
cautious approach to triglyceride reduction would seem prudent, because 
randomized trial data using fenofibrate among diabetic patients with 
elevated triglyceride have failed to find significant reduction in risk using 
this approach. 
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6. Metabolic syndrome, insulin resistance and diabetes: 
Insulin resistance and diabetes rank among the major 
cardiovascular risk factors. Insulin resistance itself promotes 
atherosclerosis even before it produces frank diabetes. 
The definition adopted by National cholesterol education program 
adult treatment panel regains atleast three of the following five criteria 
1. Waist circumference >102 cm in men and >88 cm in women 
2. Serum triglycerides of atleast 150 mg/dl 
3. HDL cholesterol <40 mg/dl in men and <50 mg/dl in women 
4. Blood pressure of atleast 130/85 mm Hg 
5. Serum glucose concentration of atleast 110 mg/dl 
Novel atherosclerotic risk factors: 
1. High sensitivity C- reactive protein 
2. Hyper homocystinemia 
3. Fibrinogen fibrin D dimer 
4. Lipoprotein (a) 
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Pathophysiology:  
Ischemic heart disease is a condition in which there is an 
inadequate supply of blood and oxygen to a portion of the myocardium. It 
typically occurs when there is an imbalance between myocardial oxygen 
supply and demand. 
Central to an understanding of the pathophysiology of myocardial 
ischemia is the concept of myocardial supply and demand. The major 
determinants of myocardial oxygen demand are heart rate, myocardial 
contractility and myocardial wall tension. About 70% of the total 
resistance to flow occurs across three sets of arteries. 
1. Large epicardial arteries R1 
2. Prearteriolar vessels R2 
3. Arteriolar and intramyocardial capillary vessels R3 
Effects of ischemia: 
Regional disturbances of ventricular contractility cause segmental 
akinesia or in severe cases bulging (dyskinesia) which can greatly reduce 
myocardial pump function. 
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When ischemia is transient, it may be associated with angina 
pectoris; when it is prolonged, it can lead to myocardial necrosis and 
scarring with or without the clinical picture of acute myocardial 
infarction. The severity and duration of the imbalance between 
myocardial oxygen supply and demand determine whether the damage is 
reversible or whether it is permenant, with subsequent myocardial 
necrosis. 
Ischemia also causes characteristic changes in the 
electrocardiogram as evidenced by inversion of T waves, when more 
severe by displacement of ST segment. Transient T wave inversion likely 
reflects non transmural, intramyocardial ischemia. Transient ST segment 
depression often reflects subendocardial ischemia and ST segment 
elevation is thought to be caused by more severe transmural ischemia. 
Another important consequence of myocardial ischemia is 
electrical instability, which may lead to isolated ventricular premature 
beats or even ventricular tachycardia or ventricular fibrillation. Most 
patients who die suddenly from IHD do as a result of ischemia induced 
tachyarrhythmia. 
Clinical features:  
Patients with IHD fall into two large group 
1. Patients with chronic coronary artery disease who most 
commonly present with stable angina 
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2. Patients with acute coronary syndrome composed of patients 
with acute MI with ST segment elevation on their presenting 
ECG (STEMI) and those with unstable angina and Non ST 
segment elevation (UA/NSTEMI)  
Almost one half of patients with UA/NSTEMI are women, while 
more than three fourths of patients with STEMI are men. 
Stable angina pectoris 
The typical patient with angina is a man older than 50 years or a 
woman older than 60 years of age who complain of chest discomfort 
usually described as heaviness, pressure, squeezing, smothering or 
choking and only rarely as frank pain. When the patient is asked to 
localize the sensation, he or she will typically place their hand over the 
sternum, sometimes with a clenched fist (Levine’s sign). 
Angina is usually crescendo decrescendo in nature typically lasts 2-
5 minutes and radiate to either shoulder and to both arms. 
However, especially in women and diabetics, angina pectoris may 
be atypical in location. The typical textbook symptoms of substernal 
chest pain or pressure radiating to the arms may not be the primary 
symptoms in women presenting with CAD. Angina equivalents are 
symptoms of myocardial ischemia other than angina. These include 
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dyspnea, nausea, fatigue and faintness and are more common in the 
elderly, women and in diabetic patients.The new onset of symptoms and 
their relationship to activity has more clinical relevance than their 
physical location. Women report symptoms more often during daily 
activities and mental stress than during exercise5. 
Unstable angina: 
Unstable angina is defined as angina pectoris or equivalent 
ischemic discomfort with atleast one of the three features1 
1. It occurs at rest (or with minimal exertion) usually lasting 
>10 minutes 
2. It is severe and of new onset (i.e. Within the prior 4-6 
weeks) 
3. It occurs with a crescendo pattern (i.e. clinically more 
severe, prolonged or frequent than previously) 
The diagnosis of NSTEMI is established if a patient with clinical 
features of unstable angina develops evidence of myocardial necrosis, as 
reflected in elevated cardiac biomarkers. 
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Clinical presentation of STEMI: 
Pain is the most common presenting complaint in patients with 
STEMI. It is similar in character to angina pectoris, but commonly occurs 
at rest, is usually more severe and lasts longer. The pain of STEMI may 
radiate as high as the occipital area but not below the umbilicus. However 
STEMI presents without pain in elderly, women and diabetics in whom it 
can present as pulmonary edema, loss of consciousness, appearance of 
arrhythmia or merely an unexplained drop in arterial pressure3. 
Physical findings: 
Although many patients have a normal pulse rate and blood 
pressure within the first hour of STEMI, about one fourth of patients with 
anterior infarction have manifestations of sympathetic nervous system 
hyperactivity such as tachycardia and/or hypertension. Upto one half of 
patients with inferior infarction show evidence of parasympathetic 
hyperactivity such as bradycardia and/or hypotension. 
1. The precardium is usually quiet and the apical impulse may 
be difficult to palpate. In patients with anterior wall 
infarction, an abnormal systolic pulsation caused by 
dyskinetic bulging of infracted myocardium may develop in 
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periapical area within the first days of illness and then may 
resolve. 
2. S3, S4 may be heard. 
3. Paradoxical splitting of S2 
4. Transient midsystolic apical systolic murmur due to 
dysfuntion of the mitral valve apparatus. 
5. Pericardial friction rub and decrease in volume of pulse 
Laboratory findings: 
The laboratory tests of value in confirming the diagnosis may be 
divided into four groups 
1. ECG 
2. Serum cardiac biomarkers 
3. Cardiac imaging 
4. Nonspecific indices of tissue necrosis and inflammation 
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ECG: 
The ECG is a cornerstone in the diagnosis of acute and chronic 
ischemic heart disease. The findings depend on several key factors: the 
nature of the process [reversible (i.e., ischemia) versus irreversible (i.e., 
infarction)], the duration (acute versus chronic), extent (transmural versus 
subendocardial), and localization (anterior versus inferoposterior), as well 
as the presence of other underlying abnormalities (ventricular 
hypertrophy, conduction defects). When the acute ischemia is transmural, 
the ST vector is usually shifted in the direction of the outer (epicardial) 
layers, producing ST elevations and sometimes, in the earliest stages of 
ischemia, tall, positive so-called hyperacute T waves over the ischemic 
zone. With ischemia confined primarily to the subendocardium, the ST 
vector typically shifts toward the subendocardium and ventricular cavity, 
so that overlying (e.g., anterior precordial) leads show ST-segment 
depression (with ST elevation in lead aVR). Profound ST elevation or 
depression in multiple leads usually indicates very severe ischemia. From 
a clinical viewpoint, the division of acute myocardial infarction into ST 
segment elevation and non-ST elevation types is useful since the efficacy 
of acute reperfusion therapy is limited to the former group. The ECG 
leads are more helpful in localizing regions of ST elevation than non-ST 
elevation ischemia. For example, acute transmural anterior (including 
apical and lateral) wall ischemia is reflected by ST elevations or 
increased T-wave positivity in one or more of the precordial leads (V1 to 
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V6) and leads I and aVL. Inferior wall ischemia produces changes in 
leads II, III, and aVF. Posterior wall ischemia may be indirectly 
recognized by reciprocal ST depressions in leads V1 to V3.Prominent 
reciprocal ST depressions in these leads also occur with certain inferior 
wall infarcts, particularly those with posterior or lateral wall extension. 
Right ventricular ischemia usually produces ST elevations in right-sided 
chest leads. When ischemic ST elevations occur as the earliest sign of 
acute infarction, they are typically followed within a period ranging from 
hours to days by evolving T-wave inversions and often by Q waves 
occurring in the same lead distribution. With infarction, depolarization 
(QRS) changes often accompany repolarization (ST-T) abnormalities. 
Necrosis of sufficient myocardial tissue may lead to decreased R-wave 
amplitude or abnormal Q waves in the anterior or inferior leads. Loss of 
depolarization forces due to posterior or lateral infarction may cause 
reciprocal increases in R-wave amplitude in leads V1 and V2 without 
diagnostic Q waves in any of the conventional leads. Atrial infarction 
may be associated with PR-segment deviations due to an atrial current of 
injury, changes in P-wave morphology, or atrial arrhythmias. In the 
weeks and months following infarction, these ECG changes may persist 
or begin to resolve. Complete normalization of the ECG following Q-
wave infarction is uncommon but may occur, particularly with smaller 
infarcts. In contrast, ST-segment elevations that persist for several weeks 
or more after a Q-wave infarct usually correlate with a severe underlying 
wall motion disorder (akinetic or dyskinetic zone), although not 
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necessarily a frank ventricular aneurysm. The ECG has important 
limitations in both sensitivity and specificity in the diagnosis of ischemic 
heart disease. Although a single normal ECG does not exclude ischemia 
or even acute infarction, a normal ECG throughout the course of an acute 
infarct is distinctly uncommon.   
Serum cardiac biomarkers: 
Certain proteins called serum cardiac biomarkers are released from 
necrotic heart muscle after STEMI. The temporal pattern of protein 
release is of diagnostic importance, but contemporary urgent reperfusion 
strategies necessitate making a decision based largely on a combination 
of clinical and ECG findings. 
Biomarkers such as cardiac specific Troponin T (CTnT) and 
cardiac specific Troponin I (CTnI) may increase after STEMI to levels 
>20 times higher than the upper reference limit. They are particularly 
valuable in differentiating skeletal muscle injury from small MI that may 
be below the detection limit for CK and CKMB measurements and they 
are therefore of particular value in distinguishing UA from NSTEMI. 
Levels of CTnT and CtnI rise as early as 3 hours after STEMI and 
elevated for 7 to 10 days after STEMI. Creatine phosphokinase rises 
within 4 to 8 hours and generally return to normal by 48 to 72 hours. A 
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ratio of CKMB: CK activity ≥2.5 suggests but is not diagnostic of a 
myocardial rather than a skeletal muscle source for the CKMB elevation. 
Cardiac imaging: 
 Abnormalities of wall motion on two-dimensional 
echocardiography are almost universally present. Although acute STEMI 
cannot be distinguished from an old myocardial scar or from acute severe 
ischemia by echocardiography, the ease and safety of the procedure make 
its use appealing as a screening tool. In the emergency department 
setting, early detection of the presence or absence of wall motion 
abnormalities by echocardiography can aid in management decisions, 
such as whether the patient should receive reperfusion therapy. 
Echocardiographic estimation of left ventricular (LV) function is useful 
prognostically; detection of reduced function serves as an indication for 
therapy with an angiotensin-converting enzyme inhibitors. 
Echocardiography may also identify the presence of right ventricular 
(RV) infarction, ventricular aneurysm, pericardial effusion, and LV 
thrombus. In addition, Doppler echocardiography is useful in the 
detection and quantitation of a ventricular septal defect and mitral 
regurgitation, two serious complications of STEMI. Several radionuclide 
imaging techniques are available for evaluating patients with suspected 
STEMI. However, these imaging modalities are used less often than 
echocardiography because they are more cumbersome and lack sensitivity 
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and specificity in many clinical circumstances. Myocardial perfusion 
imaging with 201Tl or99mTc-sestamibi, which are distributed in 
proportion to myocardial blood flow and concentrated by viable 
myocardium, reveal a defect (“cold spot”) in most patients during the first 
few hours after development of a transmural infarct. However, although 
perfusion scanning is extremely sensitive, it cannot distinguish acute 
infarcts from chronic scars and thus is not specific for the diagnosis of 
acute MI. Radionuclide ventriculography, carried out with 99mTc-labeled 
red blood cells, frequently demonstrates wall motion disorders and 
reduction in the ventricular ejection fraction in patients with STEMI. 
While of value in assessing the hemodynamic consequences of infarction 
and in aiding in the diagnosis of RV infarction when the RV ejection 
fraction is depressed, this technique is nonspecific, as many cardiac 
abnormalities other than MI alter the radionuclide ventriculogram. 
Management in the emergency department: 
The goals for management of patients with suspected STEMI 
include control of cardiac discomfort, rapid identification of patients who 
are candidates for urgent reperfusion therapy, triage of low risk patients 
to their appropriate location in the hospital and avoidance of 
inappropriate discharge of patients with STEMI. 
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Aspirin is essential in the management of patients with STEMI. 
Rapid inhibition of cyclooxygenase in platelets followed by a reduction 
of thromboxaneA2 level is achieved by buccal absorption of a chewed 
160-325mg tablet. This measure should be followed by daily oral 
administration of aspirin in a dose of 75- 162mg.  
Control of discomfort: 
Sublingual nitroglycerin upto three doses of 0.4mg should be 
administered at about 5 minutes intervals. Other drugs that can be used 
are morphine, intravenous beta blocker. 
A commonly employed regimen is metaprolol 5mg every 2-5 
minutes for a total of 3 doses provided the patient has a heart rate >60 
beats per minute, systolic pressure >100mmHg, a PR interval >0.24sec 
and rales that are no high than 10cm up from the diaphragm. Fifteen 
minutes after the last intravenous dose, an oral regimen is initiated 50mg 
every 6hrs for 48 hrs, followed by 100mg every 12hrs. 
Management strategies: 
The primary tool for screening patients and making triage decision 
is the initial 12 lead ECG. When ST segment elevation of atleast 2mm in 
two contiguous precordial leads and 1mm in two adjacent limb leads is 
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present, a patient should be considered a candidate for reperfusion 
therapy. In the absence of ST segmental elevation, fibrinolysis is not 
helpful and evidence exists suggesting that it may be harmful. 
According to ACC/AHA guidelines for the management of patients 
with STEMI, transport time to the hospital is variable from case to case, 
but the goal is to keep total ischemic time within 120 minutes. 
There are three possibilities 
1. If EMS has fibrinolytic capacity and the patient qualifies for 
therapy, prehospital fibrinolysis should be started within 30 
minutes of EMS arrival. 
2. If EMS is not capable of administering prehospital fibrinolysis and 
the patient is transported to a non PCI capable hospital, the hospital 
door to needle time should be within 30 minutes. 
3. If the patient is transported to a PCI capable hospital, the hospital 
door to balloon time should be within 90 miutes. 
Inter hospital transfer: 
 It is also appropriate to consider emergency interhospital transfer to 
a PCI capable hospital for mechanical revascularisation if 
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1. There is contraindication for fibrinolysis 
2. PCI can be initiated promptly within 90 minutes 
3. Fibrinolysis is administered and is unsuccessful (i.e. rescue PCI) 
Primary PCI: 
It appears to be more effective than fibrinolysis. It has the 
advantage of being applicable to patients who have contraindication to 
fibrinolytic therapy. Primary PCI is generally preferred when the 
diagnosis is in doubt, cardiogenic shock is present, bleeding risk is 
increased or symptoms have been present for atleast 2- 3 hours when the 
clot is more mature and less easily lysed by fibrinolytic drugs. 
Fibrinolysis: 
If no contraindications are present fibrinolytic therapy should 
ideally be initiated within 30 minutes of presentation (i.e. door to needle 
time ≤30 minutes). The principal goal of fibrinolysis is prompt restoration 
of full coronary patency. The fibrinolytic agents approved for intravenous 
use are 
1. 1.tPA 
2. Streptokinase 
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3. Tenecteplase 
4. Reteplase 
Although reduction of mortality rate is more modest, the therapy 
remains of benefit for many patients seen 3-6 hours after the onset of 
infarction and some benefit appears to be possible upto 12 hours, 
especially if chest discomfort is still present and ST segments remain 
elevated. 
tPA – 15mg bolus followed by 50mg intravenously over first 30 
minutes followed by 35mg over the next 60 minutes. 
Streptokinase – 1.5 million units intravenously over 1 hour. 
rPA – double bolus regimen 10MU bolus given over 2- 3 minutes 
followed by a second 10MU bolus 30 minutes later. 
TNK – single iv bolus 0.53mg/kg over 10 seconds.  
Contraindications and complications: 
Absolute contraindications: 
1. Cerebrovascular hemorrhage at any time 
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2. Non hemorrhagic stroke or other cerebrovascular event 
within the past year 
3. Marked hypertension >180/110mm Hg at anytime during the 
acute presentation 
4. Suspicion of aortic dissection 
5. Active internal bleeding (excluding menses) 
Relative contraindications: 
1. Current use of anticoagulants (INR ≥2) 
2. Recent i.e. < 2 weeks of invasive or surgical procedure or 
prolonged (> 10 minutes) CPR 
3. Known bleeding diathesis 
4. Pregnancy 
5. Hemorrhagic ophthalmic condition 
6. Active peptic ulcer disease 
7. A history of severe hypertension that is currently adequately 
controlled. 
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Because of the risk of an allergic reaction, patients should not 
receive streptokinase if that agent had been received within the preceding 
5 days to 2 years. Hemorrhage is the most frequent and potentially the 
most serious complication. Hemorrhagic stroke is the most serious 
complication and occurs in 0.5- 0.9% of patients being treated with these 
agents. Large scale trials have suggested that the rate of intracranial 
hemorrhage with tPA or rPA is slightly higher than with streptokinase. 
Cardiac catheterisation and coronary angiography should be carried 
out after fibrinolytic therapy if there is evidence of either 
1. Failure of reperfusion (persistent chest pain and ST 
segment elevation >90 minutes), in which case a rescue 
PCI should be considered. 
2. Coronary artery reocclusion (re-elevation of ST segment 
and/or recurrent chest pain) or the development of 
recurrent ischemia (such as recurrent angina in the early 
hospital course or a positive exercise stress test before 
discharge) in which case an urgent PCI should be 
considered. 
The potential benefits of routine angiography and elective PCI 
even in asymptomatic patients following administration of fibrinolytic 
therapy are controversial, but such an approach may have merit given the 
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numerous technological advances that have occurred in the 
catheterisation laboratory. Coronary artery bypass surgery should be 
reserved for patients whose coronary anatomy is unsuited to PCI, but in 
whom revascularisation appears to be advisable because of extensive 
jeopardized myocardium or recurrent ischemia. 
Hospital phase management: 
Coronary care units: 
The duration of stay in the coronary care unit is dictated by the 
ongoing need for intensive care. If symptoms are controlled with oral 
therapy, patients may be transferred out of the coronary care units. Also, 
patients who have confirmed to be at low risk (no prior infarction and no 
persistent chest discomfort, CHF, hypotension or cardiac arrhythmias) 
may be safely transferred out of the coronary care unit within 24 hours. 
Activity:  
Patients with STEMI should be kept at rest for the first 12 hours. In 
the absence of hypotension and other complications, by the second or 
third day patients typically are ambulating in their room with increasing 
duration and frequency. By day 3 after infarction, patients should be 
increasing their ambulation progressively to a goal of 185m atleast three 
times a day. 
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Diet: 
Because of the risk of emesis and aspiration soon after STEMI, 
patients should receive either nothing or only clear liquids by mouth for 
the first 4 – 12 hours. Portions should not be large and the menu should 
be enriched with foods that are high in potassium, magnesium and fibre 
but low in sodium. 
Bowels: 
Bed rest and the effect of narcotics used for the relief of pain often 
lead to constipation. A bedside commode rather than a bedpan, a diet rich 
in bulk and the routine use of a stool softener are recommended. 
Sedation: 
Many patients require sedation during hospitalisation to withstand 
the period of enforced inactivity with tranquility. 
Pharmacotherapy: 
Antithrombotic agents: 
The use of antiplatelet and antithrombotic therapy during the 
initial phase of STEMI is based on extensive laboratory and clinical 
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evidence that thrombosis plays an important role in the pathogenesis of 
this condition. 
1. The primary goal of treatment with antiplatelet and antithrombotic 
agents is to establish and maintain patency of the infarct related artery. 
2. The secondary goal is to reduce the patients tendency to thrombosis 
and thus the likelihood of mural thrombus  
 The most compelling evidence for the benefits of antiplatelet 
therapy mainly with aspirin in STEMI is found in the comprehensive 
overview by the Antiplatelet Trialist Collaboration. Data from nearly 
20,000 patients with MI enrolled in 15 randomized trials were pooled and 
revealed a relative reduction of 27% in the mortality rate, from 14.2% in 
control patients to 10.4% in patients receiving antiplatelet therapy. The 
addition of clopidogrel to background treatment with aspirin to STEMI 
patients reduces the risk of death, reinfarction or stroke. 
The standard antithrombotic agent used in clinical practice is 
unfractionated heparin. The recommended dose of unfractionated heparin 
is an initial bolus of 60U/Kg followed by an initial infusion of 
12U/Kg/hour. The activated partial thromboplastin time during 
maintenance therapy should be 1.5- 2 times the control value. 
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Patients with anterior location of the infarction, severe LV 
dysfunction, heart failure, a history of embolism, two dimensional 
echocardiographic evidence of mural thrombus or atrial fibrillation are at 
increased risk of systemic or pulmonary thromboembolism. Such 
individuals should receive full therapeutic levels of antithrombotic 
therapy followed by atleast three months of warfarin therapy. 
β adrenoreceptor blockers: 
Beta blocker therapy after STEMI is useful for most patients except 
those in whom it is specifically contraindicated such as patients with 
heart failure or severly compromised LV function, heart block, orthostatic 
hypotension or a history of asthma and perhaps those whose excellent 
prognosis defined as an expected mortality rate of <1% peryear, 
patients<55 years, no previous MI, with normal ventricular function, no 
complex ventricular ectopy and no angina markedly diminishes any 
potential benefit. 
Inhibition of Renin Angiotensin- Aldosterone system: 
ACE inhibitors reduce the mortality rate after STEMI and the 
mortality benefits are additive to those achieved with aspirin and beta 
blockers. Long term aldosterone blockade should be prescribed for 
STEMI patients without significant renal dysfunction (creatinine 
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≥2.5mg/dl in men and ≥2.0mg/dl in women) or hyperkalemia (potassium 
≥5.0meq/L) who are already receiving therapeutic doses of an ACE 
inhibitors. 
Complications: 
1. Ventricular dysfunction: 
The overall chamber enlargement that occurs is related to the size 
and location of the infarct, with greater dilatation following infarction of 
the anterior wall and apex of the left ventricle and causing more marked 
hemodynamic impairment, more frequent heart failure and a poorer 
prognosis. A classification originally proposed by Killip divides patients 
into four groups  
Class I: No signs of pulmonary or venous congestion. 
Class II: Moderate heart failure as evidenced by rales at the lung 
bases, S3 gallop, tachypnea or signs of right heart failure including 
venous and hepatic congestion. 
Class III: Severe heart failure, pulmonary edema. 
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Class IV: shock with systolic pressure <90mmHg and evidence    
of peripheral vasoconstriction, peripheral cyanosis, mental 
confusion and oliguria. 
2. Cardiogenic shock 
3. Arrhythmias: 
The prompt management of arrhythmias constitutes a significant 
advance in the treatment of STEMI. Pharmacological therapy is now 
reserved for patients with sustained ventricular arrhythmias 
1. Ventricular tachycardia and fibrillation 
2. Accelerated idioventricular rhythm 
3. Supraventricular arrhythmias 
4. Atrioventricular and interventricular conduction 
disturbances 
4. Pericarditis 
5. Thromboembolism  
6. Left ventricular aneurysm 
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Post infarction risk stratification and management: 
Many clinical and laboratory factors have been identified that are 
associated with an increase in cardiovascular risk after initial recovery 
from STEMI. Some of the most important risk factors include 
1. Persistent ischemia (spontaneous or provoked) 
2. Depressed LV ejection fraction <40% 
3. Rales above the lung base on physical examination or 
congestion on chest radiograph 
4. Symptomatic ventricular arrhythmias 
5. Age >75 years 
6. Diabetes 
7. History of previous myocardial infarction 
8. Hypotension  
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The usual duration of hospitalization for an uncomplicated STEMI 
is about 5 days. During the first 1- 2 weeks, the patient should be 
encouraged to increase activity by walking. After 2 weeks, the physician 
must regulate the patient’s activity on the basis of exercise tolerance. 
Most patients will be able to work within 2-4 weeks.   
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MATERIALS AND METHODS 
Hundred women admitted with acute myocardial infarction in 
coronary care unit of Govt General Hospital were randomly selected for 
the study for a period of one year from July 2008 to June 2009.   
Persons included in the study were informed about the aim of the 
study and consent was obtained. 
Information like age, symptoms, time interval to reach hospital, 
associated comorbid conditions such as hypertension, diabetes, coronary 
artery disease, family history, menstrual status, complete clinical 
examination and treatment details were collected. 
Investigations like electrocardiogram, echocardiogram, renal 
function test, lipid profile were also done. 
All the patients were followed up during their hospital stay and the 
outcome recorded. 
The collected data were analysed with regards to age of 
presentation, menstrual status, symptoms, time to reach hospital since the 
onset of symptoms, severity of clinical presentation according to Killip’s 
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classification, electrocardiographic changes and echocardiographic 
changes with in hospital outcome. 
Pump failure is now the primary cause of in hospital death due to 
STEMI. The extent of infarction correlates well with the degree of pump 
failure and with mortality both early and later2. 
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OBSERVATIONS 
Among the hundred women selected for the study, 21 were in the 
age group of 50 and below, 33 were in the 51 to 60 age group, 22 were in 
the 61 to 70 age group and 24 were in the age group of above 70. This is 
shown in Table 1 and Figure 1. The mean age is 60.97 and the range is 35 
– 85. 
Age wise distribution of cases: 
 Age in years Frequency (n = 100) 
50 and below 21 
51 – 60 33 
61 – 70 22 
Above 70 24 
Table- 1 
The interheart study which was a case control study with 15152 
cases of acute MI and 14820 controls from 262 centres of 52 countries 
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addressed the specific question of why have their first MI 9 to 10 years 
after men and concluded that younger women have lower risk factors6. 
Of the total, 43 women reached the hospital with a time interval of 
6 hours or less since the onset of symptoms. 57 of the total took more 
than 6 hours to reach the hospital. This is shown in Table 2 and Figure 2. 
Time interval to reach hospital: 
Time interval to reach hospital Frequency (n = 100) 
6 hrs or less 43 
More than 6 hrs 57 
Table - 2 
VVS Bonerjee et al state that time from onset of symptoms to 
randomization was significantly longer in women indicating a modest 
delay in time to treatment in females7. 
Of the total, 43 women experienced typical symptoms 
suggestive of angina. Remaining 57 presented with atypical symptoms. 
This is shown in Table 3. 
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Symptoms: 
Symptoms Frequency (n=100) 
Typical 43 
Atypical 57 
Table – 3 
Sheps DS et al conclude that the typical textbook symptoms of 
substernal chest pain or pressure radiating to the arms may not be the 
primary symptoms in women presenting with coronary artery disease. 
Other symptoms such as dyspnea, fatigue and lack of energy may be 
predominant3. The new onset of symptoms and their relationship to 
activity has more clinical relevance than their physical location8. 
Moreover the Rotterdam study found that the proportion of 
unrecognized MI in women was more than 54%9. The Framingham study 
also reported a higher proportion of unrecognized MI in women10. 
In this study 32 women had no risk factors at all. 49 had atleast one 
risk factor and 19 had two risk factors that can predispose to coronary 
artery disease. This is shown in Table 4. 
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Risk factors: 
Risk factors Frequency (n=100) 
0 risk factor 32 
1 risk factor 49 
2 risk factors 19 
Table – 4 
Yusuf et al, state that, for women hypertension and diabetes may 
need to be treated more aggressively. There should be greater attention to 
increased physical activity as a strategy to prevent diabetes6. 
Schatzkin et al conclude that in women, traditional risk factors 
have distinct effect on the mechanism of sudden coronary death. 
Effective risk factor modification may therefore differ between younger 
and older women and may be targeting different mechanisms of plaque 
instability11. 
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Out of the total, 26 had family history of risk factors. Remaining 
74 did not have any family history of risk factors. This is shown in Table 
5. 
Family history of risk factors: 
Family history of risk factors Frequency (n=100) 
Absent 74 
Present 26 
Table - 5 
In the study group 88 attained menopause and 12 were 
menstruating. This is shown in Table 6. 
Menstrual status: 
Menstrual status Frequency (n=100) 
Menstruating 12 
Menopause 88 
Table – 6 
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Rexrode et al state that among women, low SHBG levels were a 
marker of cardiovascular risk but this risk was not independent of BMI, 
hypertension and diabetes12.   
Patients were grouped using Killip classification of pump failure. 
45 women were grouped under class I, 26 women under class II, 28 under 
class III and one under class IV. This is shown in Table 7. 
Distribution of cases according to Killip classification: 
Killip class Frequency (n=100) 
I 45 
II 26 
III 28 
IV 1 
Table – 7 
Irrespective of the other risk factors, 88 women had a normal lipid 
profile and 12 women had an abnormal lipid profile. This is shown in 
Table 8. 
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Lipid abnormalities: 
Lipid profile Frequency (n=100) 
Normal 88 
Abnormal 12 
    Table – 8 
In the GUSTO II ACS study, involving more than 12,000 patients, 
women were older at presentation for ACS and had a higher prevalence 
of risk factors such as hypertension, diabetes and hypercholestrolemia13. 
According to the electrocardiographic manifestations, 11 women 
suffered anterolateral MI, 41 suffered anterior wall MI, 2 suffered high 
lateral MI, 29 had inferior wall MI, 3 had inferior and posterior wall MI, 
8 had inferior wall and right ventricular MI, 6 women had inferior wall, 
right ventricular and posterior wall MI. This is shown in Table 9 and 
Figure 3. 
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Electrocardiographic manifestations: 
Type of MI by ECG Frequency (n=100) 
ASMI 11 
AWMI 41 
HLMI 2 
IWMI 29 
IW&PWMI 3 
IW&RVMI 8 
IW&RV&PWMI 6 
     Table – 9 
Echocardiographic assessment of left ventricular function revealed 
that 20 women had severe LV dysfunction, another 20 had moderate LV 
dysfunction, 22 had mild LV dysfunction, and 21 had regional wall 
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motion abnormality. Out of the studied people 14 women did not have 
any regional wall motion abnormality. This is shown in Table 10. 
Echocardiographic manifestations: 
LV function by ECHO Frequency (n=100) 
No RWMA 14 
RWMA 21 
Diastolic dysfunction 3 
Mild LV dysfunction 22 
Moderate LV dysfunction 20 
Severe LV dysfunction 20 
    Table - 10 
55 women had the eligibility of being treated with thrombolytic 
therapy. 45 women were treated with heparin. This is shown in Table 11. 
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Treatment given: 
Treatment given Frequency (n=100) 
SK 55 
Heparin 45 
     Table – 11 
On short term follow up 78 recovered and 22 succumbed to death. 
This is shown in table 12. 
Outcome:   
Outcome Frequency (n=100) 
Recovered 78 
Death 22 
    Table – 12 
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On comparing age of presentation to the outcome on short term 
follow up, 15 deaths occurred in those above 60 years of age and 7 deaths 
occurred among aged 60 and below. This is statistically significant. This 
is shown in table 13 and Figure 4. 
Comparing age and outcome: 
Outcome Age in 
years 
Frequency  
(n=100) 
Recovered Death 
p value Significance 
≤ 60 yrs 54 47 7 
> 60 yrs 46 31 15 
0.0281 Significant 
Table - 13 
Hochman et al state that crude rates of death at 30 days were 
significantly higher for women14. Maynard et al have also reported that 
women with acute myocardial infarction have high in hospital mortality. 
Women were older and had more co existing conditions. After adjustment 
for such differences, many studies have concluded that sex is not an 
independent predictor of mortality after acute myocardial infarction15. 
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GUSTO II b data demonstrate that although women with acute 
coronary syndromes have increased mortality. The reason for increased 
mortality appears age dependent rather than gender dependent16. 
When the duration to reach hospital after the onset of symptoms is 
compared with outcome, 18 deaths occurred in the group of women who 
reached hospital more than 6 hours from the onset of symptoms whereas 
only 4 deaths occurred in those who reached the hospital within 6 hours 
of onset of symptoms. This is statistically significant. This is shown in 
table 14 and Figure 5. 
Comparing duration to reach hospital and outcome: 
Outcome Duration 
to reach 
hospital 
Frequency 
(n=100) 
Recovered Death 
p 
value 
Significance 
≤ 6 HRS 43 39 4 
> 6 HRS 57 39 18 
0.0080 Significant 
Table – 14 
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Mosca et al suggest that the traditional role of the female as the 
care giver rather than care seeker has been implicated in their reluctance 
to seek medical assistance for the atypical symptoms that they often 
develop. Also NSTEMI’s are more common in women. This clearly adds 
to the difficulty in diagnosing AMI in women and further confounds 
delay to initiation of appropriate treatment8, 17. 
When the mortality is compared with the presence of risk factors 
higher mortality i.e. 26.3% was noted when 2 risk factors are present. 
Whereas it is 15.63% when there is no risk factor and 24.5% in the 
presence of one risk factor. This is shown in Table 15. 
Risk factors and outcome: 
Outcome Risk factors Frequency 
(n=100) 
Recovered Death  
0 risk factor 32 27 5 (15.63%) 
1 risk factor 49 37 12 (24.5%) 
2 risk factors 19 14 5 (26.3%) 
Table - 15 
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Anand et al state that higher mortality in women after acute 
myocardial infarction is significantly related to the presence of multiple 
coexisting conditions like diabetes, hypertension, measured waist / hip 
ratio, physical activity etc18,19.  
29.82% death was recorded in those who presented with atypical 
symptoms and only 11.62% died of those who presented with typical 
symptoms. This is statistically significant.  This is shown in table 16 and 
Figure 6. 
Symptoms and outcome: 
Outcome Symptoms Frequency 
(n=100) 
Recovered Death 
p 
value 
Significance
Typical  43 38 5 
Atypical  57 40 17 
0.0495 Significant 
Table – 16 
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22.97% deaths occurred in those women who did not have a family 
history of risk factors. 19.2% deaths occurred in those women who had a 
family history of risk factors. This is shown in Table 17. 
Family history and outcome: 
Outcome  Family history of risk 
factors 
Frequency 
(n=100) 
Recovered  Death  
Absent 74 57 17(22.97%) 
Present 26 21 5 (19.2%) 
    Table – 17 
When the outcome is compared with killip classification 100% 
deaths occurred in those with class IV, 71.4% deaths occurred in class III, 
0% in class II and 2.2% deaths in those with class I was observed. This is 
shown in Table 18. 
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Killip class and outcome: 
Outcome Killip class Frequency (n=100) 
Recovered Death  
I 45 44 1 (2.2%) 
II 26 26 0 (0%) 
III 28 8 20(71.4%)
IV 1 0 1(100%) 
    Table –18 
On comparing outcome with type of myocardial infarction, 9.1% 
deaths ASMI, 19.5% deaths in AWMI, 10.3% in IWMI, 33.33% in 
IW&PWMI, 75% deaths in IW&RVMI, 50% in IW, RV&PWMI were 
observed. This is shown in Table 19. 
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Type of MI and outcome: 
Outcome Type of MI by ECG Frequency 
(n=100) 
Recovered Death  
ASMI 11 10 1 (9.1%) 
AWMI 41 33 8 (19.5%) 
HLMI 2 2 0 (0%) 
IWMI 29 26 3 (10.3%) 
IW&PWMI 3 2 1(33.33%)
IW&RVMI 8 2 6 (75%) 
IW&RV&PWMI 6 3 3 (50%) 
    Table - 19 
On studying left ventricular dysfunction, 85% deaths occurred in 
those with severe LV dysfunction. 33.3% in those with diastolic 
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dysfunction, 10% in those with moderate LV dysfunction, 9.5 % in those 
with regional wall motion abnormalities were observed. This is shown in 
Table 20. 
LV function and outcome:  
Outcome  LV function by ECHO Frequency 
(n=100) 
Recovered  Death  
No RWMA 14 14 0 (0%) 
RWMA 21 19 2 (9.5%) 
Diastolic dysfunction 3 2 1(33.33%) 
Mild LV dysfunction 22 22 0 (0%) 
Moderate LV dysfunction 20 18 2 (10%) 
Severe LV dysfunction 20 3 17 (85%) 
    Table – 20 
 56
DISCUSSION 
Cardiovascular disease is the leading cause of mortality in women. 
In fact CVD is responsible for a third of all deaths of women worldwide 
and half of all deaths of women over 50 years of age in developing 
countries20, 21. Retrospective analysis suggest that there are some 
clinically relevant differences between women and men in terms of 
prevalence, presentation, management and outcomes of the disease, but 
little is known about why CVD affects women differently. Historically, 
women have been under represented in clinical trials. The lack of good 
trial evidence concerning sex specific outcomes has led to the assumption 
about CVD treatment in women, which in turn may have resulted in 
inadequate diagnosis and sub optimal management, greatly affecting 
outcomes. This knowledge gap may also explain why cardiovascular 
health in women is not improving as fast as that of men22, 23. Over the last 
decades, mortality rates in men have steadily declined, while those in 
women remained stable. It is also becoming increasingly evident that 
gender differences in cultural, behavioral, psychosocial and socio 
economic status are responsible to various degrees, for the observed 
differences in women. However the interaction between sex and gender 
related factors and CVD outcomes in women remains largely unknown24, 
25,26.  
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This study is a cross sectional observational study. So it has its own 
limitations. Cross sectional studies are susceptible to several sources of 
bias and confounding. The study concentrates about the age of 
presentation, symptoms, delay in treatment, clinical profile, 
complications and short term mortality. 
Hundred patients admitted to coronary care unit with evidence of 
acute myocardial infarction features in electrocardiogram were randomly 
selected and data collected with the follow up during the hospital stay of 
patients. 
In this study the mean age is 60.97 and the range is 35 – 85. Total 
mortality is 22% and there is a significant correlation between mortality 
and age. Women of advanced age develop more complications and 
mortality. Johanne Neil et al state that the excess mortality in women is 
due to older age at presentation in women27, 28. 
63% women presented with atypical symptoms. This study 
concludes that women classically present at an advanced age, with 
atypical symptoms resulting in a delay of initiation of treatment or 
inadequate treatment leading to poor short term outcome. There is a 
significant delay in reaching the treatment care center. In this study there 
is significant correlation between time to receive treatment since the onset 
of symptoms and poor short term outcome. Sandra et al state that, women 
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receive somewhat less aggressive treatment during the early management 
of acute myocardial infarction29, 30. Hani Jneid et al state that the under 
use of evidence based treatments and delayed reperfusion among women 
represent potential opportunities for reducing poor outcomes after AMI31. 
Those women who developed MI at an age younger than 60 years 
had more than one risk factor. Risk factors such as diabetes, hypertension 
play an important role in predisposing younger women to CAD. So 
aggressive treatment of diabetes and hypertension should be encouraged 
in women. This is consistent with previous studies. Burke et al state that, 
in women traditional risk factors have distinct effects on the mechanism 
of sudden coronary death, which vary by menopausal status. Effective 
risk factor modification may therefore differ between younger and older 
women and may targeting different mechanisms of plaque rupture32, 33. 
88% of women were postmenopausal. Significant percentage of 
women presented with advanced stages in Killip classification. 
The most common pattern of myocardial infarction is anterior wall 
myocardial infarction.62% of women had Lvdysfunction and out of them 
20% had severe LV dysfunction. 55% were eligible enough to receive 
adequate thrombolytic therapy.     
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CONCLUSION 
1. Women with advanced age have a poorer outcome. 
2. Women clinically present with atypical symptoms that has resulted in 
a significant delay to reach treatment centre. 
3. In hospital mortality is directly related to atypical symptoms, delay in 
reaching the hospital and co morbidities. 
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PROFORMA  
SERIAL NO: 
 
NAME:     AGE:    SEX: 
 
ADDRESS: 
 
 
 
         
 
OCCUPATION:      INCOME: 
 
 
IP NO:    DOA:    DOD: 
 
 
TIME INTERVAL TO REACH HOSPITAL: 
 
 
COMPLAINTS: 
 
 
 
PRESENT HISTORY:  Chest Pain - Typical/Atypical 
    Palpitation 
    Syncope 
    Dyspnea 
PND, Orthopnea 
Giddiness 
Nausea, Vomiting 
 
PAST HITORY:  DM/HT/IHD/CVA 
 
 
FAMILY HISTORY: DM/HT/CAD/Premature IHD 
 
 
PERSONAL HISTORY: Smoking/Alcoholic/Diet/Oral Contraceptive 
Pills/HRT 
 
MENSTRUAL HISTORY: 
EXAMINATION: 
General Examination: 
   Anemia/Jaundice/Pedal edema/ Dyspnea 
   Pulse:  BP:   JVP: 
 
Cardiovascular System Examination: 
   Heart sounds: 
   Murmur: 
   Pericardial rub: 
   Killip class: 
 
Respiratory System Examination: 
 
Abdomen Examination: 
 
Central Nervous System Examination: 
 
INVESTIGATIONS: 
 
Urine - Albumin 
  Sugar 
  Deposits 
Blood - Sugar 
  Urea 
Creatinine 
 
Lipid Profile- Total Cholesterol 
   TGL 
   LDL 
   HDL 
   VLDL 
Chest X Ray: 
 
ECG: 
 
ECHO: 
 
TREATMENT GIVEN: 
 
OUTCOME: 
ABBREVIATIONS 
 
 
CVD - Cardio vascular disease 
CAD - Coronary artery disease 
IHD - Ischemic heart disease 
ECG - Electrocardiogram 
STEMI - ST elevation MI 
MI - Myocardial infarction 
DASH - Dietary approaches to stop hypertension 
BP - Blood pressure 
HDL - High density lipoprotein 
LDL - Low density lipoprotein 
UA - Unstable angina 
CK - Creatine kinase 
CK – MB - Creatine kinase - MB 
Tc - Technitium 
ACC - American college of cardiology 
AHA - American heart association 
EMS - Emergency medical services 
PCI - Percutaneous coronary intervention 
CPR - Cardio pulmonary resuscitation 
INR - International normalized ratio 
TNK - Tenecteplase 
rPA - Reteplase 
ACE - Angiotensin converting enzyme 
LV - Left ventricle 
SHBG - Sex hormone binding globulin 
BMI - Body mass index 
RWMA - Regional wall motion abnormality 
SK - Streptokinase 
ACS - Acute coronary syndrome 
AWMI - Anterior wall myocardial infarction 
ASMI - Antero septal myocardial infarction 
IWMI - Inferior wall myocardial infarction 
RVMI - Right ventricular myocardial infarction 
PWMI - Posterior wall myocardial infarction 
HLMI - High lateral myocardial infarction 
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Figure - 5 
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Serial 
No Age
Time 
interval to 
reach 
hospital
Symptoms 
Typical/ 
Atypical
Past 
history 
DM/HT/ 
CAD/CVA
Family 
history 
DM/HT/ 
CAD     
Menstrual 
history
Killip 
class
Lipid 
profile ECG ECHO Treatment given Outcome
1 46 01 HR Typical DM DM MP I TGL IWMI&RVMI RWMA SK RECOVERED
2 70 08 HRS Atypical HT NIL MP I N IWMI NO RWMA SK RECOVERED
3 69 12 HRS Atypical DM/HT DM,CAD MP III TGL IWMI DD HEPARIN&NTG DEATH
4 50 72 HRS Atypical DM NIL MP III N AWMI RWMA HEPARIN&NTG RECOVERED
5 49 96 HRS Atypical DM/HT DM,HT MP II TGL,LDL AWMI MILD LV DYSFN HEPARIN RECOVERED
6 48 48 HRS Typical NIL NIL MP I N ASMI MOD LV DYS HEPARIN RECOVERED
7 67 96 HRS Atypical DM NIL MP III N AWMI RWMA&VSR HEPARIN DEATH
8 35 04 HRS Atypical DM/IHD DM M II TGL HLMI RWMA SK RECOVERED
9 75 04 HRS Atypical DM/HT DM MP III N AWMI SEV LV DYSFN SK DEATH
10 75 12 HRS Atypical HT NIL MP III N IWMI MILD LV DYSFN HEPARIN RECOVERED
11 75 12 HRS Atypical CAD NIL MP IV N IWMI&RVMI SEV LV DYSFN SK DEATH
12 45 04 HRS Typical HT HT M I TGL AWMI MILD LV DYSFN SK RECOVERED
13 57 02 HRS Typical NIL NIL MP I N AWMI RWMA SK RECOVERED
14 70 08 HRS Typical NIL NIL MP I N AWMI RWMA SK RECOVERED
15 56 14 HRS Atypical DM/HT NIL MP I N IWMI NO RWMA HEPARIN RECOVERED
16 75 10 HRS Typical NIL NIL MP II N AWMI MILD LV DYSFN HEPARIN RECOVERED
17 60 06 HRS Atypical DM/HT DM MP III N IWMI NO RWMA SK RECOVERED
18 47 04 HRS Atypical DM/HT NIL M I TGL,LDL ASMI NO RWMA SK RECOVERED
19 55 12 HRS Atypical NIL CAD MP II N AWMI MILD LV DYSFN HEPARIN&NTG RECOVERED
20 57 14 HRS Atypical HT NIL MP I N IWMI DD HEPARIN RECOVERED
21 70 04 HRS Atypical DM/HT NIL MP III N IW&PW&RVMI MOD LV DYS SK DEATH
22 57 12 HRS Atypical NIL CAD MP I TGL ASMI MILD LV DYSFN HEPARIN RECOVERED
23 45 06 HRS Atypical DM/HT NIL M I TGL IWMI RWMA SK RECOVERED
24 47 24 HRS Atypical DM/HT NIL M III N IWMI DD HEPARIN RECOVERED
25 60 48 HRS Atypical HT NIL MP III N IW&PW&RVMI SEV LV DYSFN HEPARIN DEATH
26 60 20 HRS Atypical DM NIL MP III N IW&PW&RVMI MILD LV DYSFN HEPARIN RECOVERED
27 68 48 HRS Atypical DM NIL MP II N IWMI RWMA HEPARIN RECOVERED
28 56 06 HRS Typical HT NIL MP II N IWMI MILD LV DYSFN SK RECOVERED
29 40 24 HRS Atypical DM DM M II LDL AWMI MOD LV DYS HEPARIN RECOVERED
30 60 06 HRS Typical HT NIL MP III N AWMI SEV LV DYSFN SK RECOVERED
                                                                                                MASTER CHART
31 55 20 HRS Atypical HT/CAD CAD MP I N ASMI RWMA HEPARIN RECOVERED
32 65 20 HRS Atypical HT/CAD HT MP II N AWMI MILD LV DYSFN HEPARIN RECOVERED
33 43 22 HRS Atypical DM DM MP III TGL AWMI MOD LV DYS HEPARIN DEATH
34 73 28 HRS Typical NIL NIL MP III N IW&RVMI SEV LV DYSFN HEPARIN DEATH
35 45 04 HRS Typical HT CAD M I N IWMI NO RWMA SK RECOVERED
36 63 48 HRS Atypical NIL NIL MP I N AWMI MILD LV DYSFN HEPARIN RECOVERED
37 62 06 HRS Typical HT NIL MP I N ASMI NO RWMA HEPARIN RECOVERED
38 35 02 HRS Typical HT CAD M I N AWMI RWMA SK RECOVERED
39 45 06 HRS Typical CAD NIL M II TGL,LDL IWMI MILD LV DYSFN SK RECOVERED
40 50 12 HRS Atypical DM DM M III TGL IWMI&PWMI SEV LV DYSFN HEPARIN DEATH
41 76 06 HRS Typical NIL NIL MP II N AWMI MOD LV DYS SK RECOVERED
42 60 02 HRS Typical HT NIL MP I N AWMI&LBBB MILD LV DYSFN SK RECOVERED
43 57 02 HRS Typical DM NIL MP II N IWMI RWMA SK RECOVERED
44 80 12 HRS Atypical NIL NIL MP III N AWMI SEV LV DYSFN HEPARIN DEATH
45 54 10 HRS Atypical DM NIL MP I N AWMI NO RWMA HEPARIN RECOVERED
46 81 20 HRS Atypical HT NIL MP I N IWMI NO RWMA HEPARIN RECOVERED
47 54 12 HRS Atypical HT/DM NIL MP III N IW&RV& PWMI SEV LV DYSFN HEPARIN DEATH
48 72 02 HRS Typical HT NIL MP III N IWMI SEV LV DYSFN SK DEATH
49 85 10 HRS Atypical DM NIL MP III N IWMI&CHB SEV LV DYSFN HEPARIN DEATH
50 57 06 HRS Typical NIL NIL MP II N AWMI MOD LV DYS SK RECOVERED
51 45 02 HRS Typical NIL NIL MP I N IWMI RWMA SK RECOVERED
52 74 04 HRS Typical NIL NIL MP I N AWMI MILD LV DYSFN SK RECOVERED
53 57 12 HRS Atypical HT NIL MP I N AWMI MILD LV DYSFN HEPARIN RECOVERED
54 55 10 HRS Atypical DM DM MP I N AWMI MILD LV DYSFN HEPARIN RECOVERED
55 62 12 HRS Atypical DM/HT NIL MP III N AWMI SEV LV DYSFN HEPARIN DEATH
56 76 10 HRS Atypical DM NIL MP III N AWMI SEV LV DYSFN HEPARIN DEATH
57 55 24 HRS Atypical DM/HT HT MP III N AWMI&CHB SEV LV DYSFN HEPARIN RECOVERED
58 39 02 HRS Typical DM/HT DM,HT M II N AWMI MOD LV DYS SK RECOVERED
59 52 06 HRS Typical HT HT MP I N IWMI RWMA SK RECOVERED
60 56 07 HRS Atypical HT NIL MP I N AWMI RWMA SK DEATH
61 75 08 HRS Typical NIL NIL MP III N AWMI SEV LV DYSFN SK DEATH
62 72 08 HRS Typical NIL NIL MP III N AWMI SEV LV DYSFN SK RECOVERED
63 60 02 HRS Typical HT NIL MP II N ASMI MOD LV DYS SK RECOVERED
64 53 02 HRS Atypical DM DM,CAD MP I N IW&PWMI MOD LV DYS SK RECOVERED
65 65 06 HRS Typical NIL NIL MP II N IW&PW&RVMI MILD LV DYSFN SK RECOVERED
66 75 12 HRS Atypical NIL NIL MP II N AWMI MOD LV DYS SK RECOVERED
67 65 02 HRS Typical NIL NIL MP I N AWMI MILD LV DYSFN SK RECOVERED
68 76 12 HRS Atypical DM/HT NIL MP I N AWMI RWMA HEPARIN RECOVERED
69 65 10 HRS Atypical NIL NIL MP I N AWMI RWMA SK RECOVERED
70 45 12 HRS Atypical DM NIL MP I N ASMI NO RWMA HEPARIN RECOVERED
71 63 02 HRS Typical HT NIL MP I N ASMI NO RWMA SK RECOVERED
72 65 10 HRS Atypical NIL CAD MP I N IW&PWMI RWMA SK RECOVERED
73 49 02 HRS Typical CAD NIL MP II N IW&PW&RVMI MOD LV DYS SK RECOVERED
74 43 12 HRS Typical HT NIL M I N IWMI NO RWMA HEPARIN RECOVERED
75 55 07 HRS Atypical HT NIL MP III N IW&RVMI&AF SEV LV DYSFN SK DEATH
76 52 07 HRS Typical HT NIL MP II N IW&RWMI MOD LV DYS SK RECOVERED
77 75 10 HRS Atypical NIL NIL MP II N IWMI MOD LV DYS SK RECOVERED
78 61 06 HRS Atypical HT NIL MP I N ASMI MILD LV DYSFN SK RECOVERED
79 60 02 HRS Typical NIL DM MP I N IWMI NO RWMA SK RECOVERED
80 60 04 HRS Typical DM DM MP III N ASMI SEV LV DYSFN SK DEATH
81 57 02 HRS Atypical DM/HT NIL MP I N AWMI RWMA SK RECOVERED
82 85 02 HRS Atypical NIL NIL MP I N IWMI NO RWMA SK RECOVERED
83 65 12HRS Atypical NIL NIL MP II N AWMI MOD LV DYS HEPARIN RECOVERED
84 75 02 HRS Typical NIL NIL MP II N AWMI MOD LV DYS SK RECOVERED
85 48 02 HRS Typical HT NIL MP I N ASMI RWMA SK RECOVERED
86 52 12 HRS Atypical HT NIL MP I N IWMI NO RWMA HEPARIN RECOVERED
87 70 12 HRS Typical NIL NIL MP II N IWMI MOD LV DYS HEPARIN RECOVERED
88 70 20 HRS Atypical NIL NIL MP III N IW&RVMI SEV LV DYSFN HEPARIN DEATH
89 80 24 HRS Atypical HT NIL MP III N IW&RVMI&CHB SEV LV DYSFN SK DEATH
90 75 02 HRS Atypical HT NIL MP I N IWMI MILD LV DYSFN SK RECOVERED
91 65 12 HRS Typical NIL NIL MP III N IW&RVMI SEV LV DYSFN HEPARIN DEATH
92 70 12 HRS Atypical NIL NIL MP II N IWMI MOD LV DYS HEPARIN RECOVERED
93 72 10 HRS Atypical NIL NIL MP II N AWMI MOD LV DYS HEPARIN RECOVERED
94 60 12 HRS Typical HT NIL MP I N HLMI MILD LV DYSFN HEPARIN RECOVERED
95 70 10 HRS Atypical DM NIL MP II N IWMI MOD LV DYS HEPARIN RECOVERED
96 75 05 HRS Typical NIL NIL MP I N AWMI MILD LV DYSFN SK RECOVERED
97 55 06 HRS Typical DM/HT DM,HT MP II N IWMI MOD LV DYS SK RECOVERED
98 60 02 HRS Typical DM DM MP I N AWMI MILD LV DYSFN SK RECOVERED
99 72 04 HRS Typical NIL NIL MP I N IWMI RWMA SK RECOVERED
100 60 02 HRS Typical HT NIL MP I N AWMI RWMA SK RECOVERED
